Financial Ratios APT Medical Inc.
Equities
688617
CNE100004C45
Medical Equipment, Supplies & Distribution
|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 229.38 CNY | -0.27% |
|
-1.13% | -5.71% |
| 01-28 | Tranche Update on APT Medical Inc.'s Equity Buyback Plan announced on December 9, 2025. | CI |
| 01-28 | APT Medical Buys Back Shares for 250 Million Yuan | MT |
| Fiscal Period: December | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|---|---|
Profitability | ||||||||
Return on Assets | 11.49 | 8.49 | 10.76 | 13.67 | 16.06 | |||
Return on Total Capital | 13.57 | 9.49 | 12.39 | 16.84 | 19.32 | |||
Return On Equity % | 26.18 | 17.39 | 18.99 | 27.82 | 29.14 | |||
Return on Common Equity | 27.35 | 18.58 | 20.22 | 29.09 | 30.44 | |||
Margin Analysis | ||||||||
Gross Profit Margin % | 70.35 | 68.74 | 70.89 | 70.54 | 71.93 | |||
SG&A Margin | 31.98 | 30.22 | 25.29 | 23.45 | 22.48 | |||
EBITDA Margin % | 26.17 | 24.65 | 33.3 | 35.15 | 38.25 | |||
EBITA Margin % | 22.52 | 21.41 | 30.14 | 32.03 | 34.82 | |||
EBIT Margin % | 22.04 | 21.32 | 30.02 | 31.81 | 34.54 | |||
Income From Continuing Operations Margin % | 21.73 | 23.51 | 27.97 | 31.64 | 31.86 | |||
Net Income Margin % | 23.11 | 25.09 | 29.44 | 32.35 | 32.59 | |||
Net Avail. For Common Margin % | 23.11 | 25.09 | 29.44 | 32.35 | 32.59 | |||
Normalized Net Income Margin | 15.02 | 15.67 | 21.42 | 21.6 | 23.08 | |||
Levered Free Cash Flow Margin | 8.1 | -4.12 | 21.81 | 21.45 | -16 | |||
Unlevered Free Cash Flow Margin | 8.29 | -3.99 | 21.89 | 21.59 | -15.94 | |||
Asset Turnover | ||||||||
Asset Turnover | 0.83 | 0.64 | 0.57 | 0.69 | 0.74 | |||
Fixed Assets Turnover | 3.32 | 4 | 4.2 | 4.21 | 3.64 | |||
Receivables Turnover (Average Receivables) | 10.53 | 21.17 | 29.68 | 36.92 | 32.77 | |||
Inventory Turnover (Average Inventory) | 0.99 | 1.27 | 1.18 | 1.46 | 1.59 | |||
Short Term Liquidity | ||||||||
Current Ratio | 3.2 | 7.98 | 3.78 | 2.99 | 3.98 | |||
Quick Ratio | 1.55 | 6.53 | 2.9 | 2.36 | 2.92 | |||
Operating Cash Flow to Current Liabilities | 1.35 | 0.93 | 0.89 | 1.17 | 1.83 | |||
Days Sales Outstanding (Average Receivables) | 34.76 | 17.24 | 12.3 | 9.89 | 11.17 | |||
Days Outstanding Inventory (Average Inventory) | 370.94 | 287.77 | 309.9 | 249.98 | 229.51 | |||
Average Days Payable Outstanding | 22.12 | 12.68 | 22.41 | 24.61 | 25.02 | |||
Cash Conversion Cycle (Average Days) | 383.58 | 292.33 | 299.78 | 235.25 | 215.66 | |||
Long Term Solvency | ||||||||
Total Debt/Equity | 8.69 | 2.6 | 2.94 | 4.58 | 0.44 | |||
Total Debt / Total Capital | 7.99 | 2.53 | 2.85 | 4.38 | 0.44 | |||
LT Debt/Equity | 5.24 | 0.95 | 0.51 | 0.44 | 0.19 | |||
Long-Term Debt / Total Capital | 4.82 | 0.93 | 0.49 | 0.42 | 0.19 | |||
Total Liabilities / Total Assets | 23.55 | 11.03 | 19.54 | 23.75 | 14.29 | |||
EBIT / Interest Expense | 74.77 | 108.65 | 251.42 | 142.29 | 355.86 | |||
EBITDA / Interest Expense | 88.79 | 129.06 | 284.15 | 159.64 | 399.11 | |||
(EBITDA - Capex) / Interest Expense | 57.51 | 26.13 | 185.51 | 104.87 | 74.83 | |||
Total Debt / EBITDA | 0.31 | 0.22 | 0.13 | 0.15 | 0.01 | |||
Net Debt / EBITDA | -0.65 | -5.61 | -2.62 | -2.12 | -1.34 | |||
Total Debt / (EBITDA - Capex) | 0.48 | 1.1 | 0.2 | 0.23 | 0.08 | |||
Net Debt / (EBITDA - Capex) | -1 | -27.7 | -4.01 | -3.22 | -7.13 | |||
Growth Over Prior Year | ||||||||
Total Revenues, 1 Yr. Growth % | 18.68 | 72.85 | 46.74 | 35.71 | 25.18 | |||
Gross Profit, 1 Yr. Growth % | 18.02 | 68.87 | 51.33 | 35.05 | 27.65 | |||
EBITDA, 1 Yr. Growth % | 22.16 | 61.47 | 99 | 42.99 | 36.04 | |||
EBITA, 1 Yr. Growth % | 20.29 | 62.8 | 107.46 | 43.89 | 35.88 | |||
EBIT, 1 Yr. Growth % | 20.03 | 65.93 | 107.76 | 43.8 | 35.96 | |||
Earnings From Cont. Operations, 1 Yr. Growth % | 33.45 | 87.01 | 74.57 | 53.5 | 26.05 | |||
Net Income, 1 Yr. Growth % | 34.15 | 87.7 | 72.19 | 49.13 | 26.08 | |||
Normalized Net Income, 1 Yr. Growth % | 21.22 | 78.12 | 101.59 | 36.87 | 33.73 | |||
Diluted EPS Before Extra, 1 Yr. Growth % | 34.54 | 42.79 | 67.2 | 49.43 | 26.74 | |||
Accounts Receivable, 1 Yr. Growth % | -7.11 | -22.2 | 38.62 | -11.39 | 99.37 | |||
Inventory, 1 Yr. Growth % | 1.7 | 81.21 | 28.37 | -2.96 | 21.76 | |||
Net Property, Plant and Equip., 1 Yr. Growth % | 16.25 | 66.81 | 23.65 | 45.18 | 44.59 | |||
Total Assets, 1 Yr. Growth % | 4.93 | 241.95 | 10.58 | 15.59 | 15.85 | |||
Tangible Book Value, 1 Yr. Growth % | 74.06 | 307.99 | -1.22 | 2.99 | 16.34 | |||
Common Equity, 1 Yr. Growth % | 31.69 | 286.25 | -0.83 | 8.16 | 31.94 | |||
Cash From Operations, 1 Yr. Growth % | 170.03 | 22.36 | 102.58 | 87.52 | 7.88 | |||
Capital Expenditures, 1 Yr. Growth % | -34.58 | 278.68 | -14.44 | 41.08 | 221.86 | |||
Levered Free Cash Flow, 1 Yr. Growth % | -178.47 | -185.88 | -842.59 | 34.29 | -193.57 | |||
Unlevered Free Cash Flow, 1 Yr. Growth % | -180.52 | -182.24 | -866.96 | 34.7 | -192.61 | |||
Dividend Per Share, 1 Yr. Growth % | - | 100 | 65.01 | 21.2 | 26.88 | |||
Compound Annual Growth Rate Over Two Years | ||||||||
Total Revenues, 2 Yr. CAGR % | 40.82 | 43.23 | 59.26 | 41.12 | 30.34 | |||
Gross Profit, 2 Yr. CAGR % | 42.42 | 41.17 | 59.86 | 42.96 | 31.3 | |||
EBITDA, 2 Yr. CAGR % | 118.74 | 41.01 | 78.93 | 68.84 | 39.57 | |||
EBITA, 2 Yr. CAGR % | 150.4 | 40.6 | 83.39 | 72.95 | 39.94 | |||
EBIT, 2 Yr. CAGR % | 148.57 | 41.67 | 85.14 | 72.85 | 39.83 | |||
Earnings From Cont. Operations, 2 Yr. CAGR % | 149.97 | 57.98 | 80.68 | 63.7 | 39.1 | |||
Net Income, 2 Yr. CAGR % | 126.92 | 58.68 | 79.78 | 60.25 | 37.12 | |||
Normalized Net Income, 2 Yr. CAGR % | 111.84 | 47.83 | 89.03 | 66.11 | 35.29 | |||
Diluted EPS Before Extra, 2 Yr. CAGR % | 127.23 | 38.6 | 54.51 | 58.06 | 37.59 | |||
Accounts Receivable, 2 Yr. CAGR % | 31.17 | -14.99 | 3.85 | 10.83 | 32.91 | |||
Inventory, 2 Yr. CAGR % | 34.44 | 35.76 | 52.52 | 11.62 | 8.7 | |||
Net Property, Plant and Equip., 2 Yr. CAGR % | 24.1 | 39.25 | 43.62 | 33.98 | 44.88 | |||
Total Assets, 2 Yr. CAGR % | 34.42 | 89.43 | 94.45 | 13.05 | 15.72 | |||
Tangible Book Value, 2 Yr. CAGR % | 26.16 | 166.49 | 100.75 | 0.86 | 9.46 | |||
Common Equity, 2 Yr. CAGR % | 30.61 | 125.53 | 95.71 | 3.56 | 19.46 | |||
Cash From Operations, 2 Yr. CAGR % | 182.07 | 81.77 | 57.44 | 94.9 | 42.23 | |||
Capital Expenditures, 2 Yr. CAGR % | 17.17 | 57.39 | 80 | 9.86 | 113.09 | |||
Levered Free Cash Flow, 2 Yr. CAGR % | 61.65 | -16.99 | 158.38 | 214.83 | 11.97 | |||
Unlevered Free Cash Flow, 2 Yr. CAGR % | 64.41 | -18.1 | 157.14 | 220.45 | 11.56 | |||
Dividend Per Share, 2 Yr. CAGR % | - | - | 81.67 | 41.42 | 24.01 | |||
Compound Annual Growth Rate Over Three Years | ||||||||
Total Revenues, 3 Yr. CAGR % | 46.28 | 50.77 | 44.39 | 50.99 | 35.59 | |||
Gross Profit, 3 Yr. CAGR % | 47.36 | 50.74 | 44.48 | 51.12 | 37.66 | |||
EBITDA, 3 Yr. CAGR % | 85.94 | 98.22 | 57.98 | 66.14 | 57.18 | |||
EBITA, 3 Yr. CAGR % | 107.44 | 117.6 | 59.84 | 69.26 | 59.67 | |||
EBIT, 3 Yr. CAGR % | 106.54 | 117.8 | 60.65 | 70.18 | 59.56 | |||
Earnings From Cont. Operations, 3 Yr. CAGR % | 56.7 | 126.92 | 63.33 | 71.12 | 50.04 | |||
Net Income, 3 Yr. CAGR % | 47.55 | 113.01 | 63.06 | 68.92 | 47.94 | |||
Normalized Net Income, 3 Yr. CAGR % | 40.06 | 100.76 | 63.67 | 69.75 | 54.53 | |||
Diluted EPS Before Extra, 3 Yr. CAGR % | 47.65 | 94.63 | 47.55 | 52.8 | 46.83 | |||
Accounts Receivable, 3 Yr. CAGR % | 13.39 | 10.21 | 0.06 | -1.5 | 34.79 | |||
Inventory, 3 Yr. CAGR % | 49.1 | 48.51 | 33.25 | 31.18 | 14.9 | |||
Net Property, Plant and Equip., 3 Yr. CAGR % | 30.8 | 36.96 | 33.85 | 44.14 | 37.43 | |||
Total Assets, 3 Yr. CAGR % | 32.56 | 83.5 | 58.31 | 63.5 | 13.98 | |||
Tangible Book Value, 3 Yr. CAGR % | 26.17 | 86.57 | 91.43 | 60.71 | 5.78 | |||
Common Equity, 3 Yr. CAGR % | 29.05 | 87.48 | 71.5 | 60.61 | 12.27 | |||
Cash From Operations, 3 Yr. CAGR % | 125.58 | 113.53 | 88.46 | 66.89 | 60.03 | |||
Capital Expenditures, 3 Yr. CAGR % | 20.5 | 73.23 | 28.45 | 65.96 | 57.2 | |||
Levered Free Cash Flow, 3 Yr. CAGR % | - | 31.9 | 74.98 | 107.32 | 109.94 | |||
Unlevered Free Cash Flow, 3 Yr. CAGR % | - | 31.07 | 75.37 | 106.87 | 111.7 | |||
Dividend Per Share, 3 Yr. CAGR % | - | - | - | 58.74 | 36.4 | |||
Compound Annual Growth Rate Over Five Years | ||||||||
Total Revenues, 5 Yr. CAGR % | - | - | 51.34 | 46.83 | 38.6 | |||
Gross Profit, 5 Yr. CAGR % | - | - | 52.24 | 47.58 | 39.05 | |||
EBITDA, 5 Yr. CAGR % | - | - | 83.4 | 85.76 | 50.39 | |||
EBITA, 5 Yr. CAGR % | - | - | 97.83 | 98.33 | 51.62 | |||
EBIT, 5 Yr. CAGR % | - | - | 98 | 98.34 | 51.97 | |||
Earnings From Cont. Operations, 5 Yr. CAGR % | - | - | 65.88 | 99.13 | 53.17 | |||
Net Income, 5 Yr. CAGR % | - | - | 59.68 | 90.09 | 52.14 | |||
Normalized Net Income, 5 Yr. CAGR % | - | - | 58.29 | 85.93 | 51.67 | |||
Diluted EPS Before Extra, 5 Yr. CAGR % | - | - | 50.36 | 79.08 | 43.48 | |||
Accounts Receivable, 5 Yr. CAGR % | - | - | 9.47 | 10.46 | 12.1 | |||
Inventory, 5 Yr. CAGR % | - | - | 50.46 | 32.48 | 22.83 | |||
Net Property, Plant and Equip., 5 Yr. CAGR % | - | - | 35.78 | 35.76 | 38.16 | |||
Total Assets, 5 Yr. CAGR % | - | - | 54.51 | 51.18 | 39.66 | |||
Tangible Book Value, 5 Yr. CAGR % | - | - | 51.93 | 45.88 | 53.08 | |||
Common Equity, 5 Yr. CAGR % | - | - | 52.44 | 47.86 | 48.4 | |||
Cash From Operations, 5 Yr. CAGR % | - | - | 95.36 | 105.87 | 68.4 | |||
Capital Expenditures, 5 Yr. CAGR % | - | - | 41.48 | 44.39 | 57.28 | |||
Levered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 88.52 | 46.18 | |||
Unlevered Free Cash Flow, 5 Yr. CAGR % | - | - | - | 89.19 | 46.17 |
- Stock Market
- Equities
- 688617 Stock
- Financials APT Medical Inc.
- Financial Ratios
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition















